An observational study in Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium. Recruiting at 17 sites in 2 countries. Open to participants aged 31 Days to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by New Approaches to Neuroblastoma Therapy Consortium · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium — 3 open to participants now, 6 under way, none of them phase 3. Neuroblastoma · New Approaches to Neuroblastoma Therapy Consortium.
Among the 24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium, this one is the only one that started in 2011, is one of 2 observational ones, and was the 13th registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →3 of the 24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium are open now, in 2 countries. Recruiting first, the newest first:
New Approaches to Neuroblastoma Therapy Consortium · Sites in United States
Ages 1–31
New Approaches to Neuroblastoma Therapy Consortium · Sites in United States
Ages 1–30
By country, each count listing its studies:
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: 31 Days to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 5
First in 1996; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 123 across 84 observational studies indexed under Neuroblastoma.
Median enrollment 31 across the 20 interventional studies, 547 across the 2 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
New Approaches to Neuroblastoma Therapy Consortium is the lead sponsor of 24 studies on the registry; 3 are open to participants now.
3 of the studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02298348New Approaches to Neuroblastoma Therapy ConsortiumSorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | 2026-12 |
| NCT02868268New Approaches to Neuroblastoma Therapy ConsortiumNeuroblastoma Precision Trial | 2026-12 |
| NCT02573896New Approaches to Neuroblastoma Therapy ConsortiumImmunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.
The purposes of this study are:
To establish a storage place or bank of samples of blood, bone marrow, and/or tumor, and molecular components isolated from these samples from children with neuroblastoma. The stored specimens will be shared with laboratory researchers studying high risk neuroblastoma.
To collect clinical data (such as treatments received, date of diagnosis, tumor stage, etc) and radiology scans to provide this information as needed for the laboratory studies to be done on the specimens.
To obtain neuroblastoma tumor cells from tumor tissue, bone marrow, and/or blood to use to start cell lines, or tumor cells that will keep growing in the laboratory. These cell lines will be shared with laboratory researchers studying high risk neuroblastoma.
Neuroblastoma patients from various NANT sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Not enrolling at this site.
Not enrolling at this site.
The record gives a start of Jul 2011, a primary completion of Dec 2099 and a completion of Dec 2099. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
New Approaches to Neuroblastoma Therapy Consortium